智通财经APP获悉，归创通桥(02190)绩后涨超4%，截至发稿，涨3.59%，报24.22港元，成交额603.11万港元。
消息面上，近日，归创通桥发布截至2025年6月30日止六个月的中期业绩，收入4.82亿元(人民币，下同)，同比增加31.69%；毛利3.43亿元，同比增加31.5%；股东应占溢利1.21亿元，同比增加76%；每股基本盈利0.38元。
公告称，集团介入产品收入的63.3%来自神经血管介入产品业务，36.7%来自外周血管介入产品业务。集团收入的显著增长主要归因于神经血管和外周血管介入器械分部的销售额高速增长。
于2025年上半年，神经血管介入产品的销售收入较2024年上半年增加25.0%，主要是由于：银蛇颅内中间导管系列、凤颅内动脉瘤栓塞弹簧圈及神经血管导丝等主要成熟产品的收入大幅增长；在医院大规模集中采购之后，在全国推出麒麟血流导向装置等相对较新的产品；及集团持续致力于提高产品在各级医院的渗透率。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.